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ABSTRACT
Background: Rheumatoid arthritis (RA) is an incurable autoimmune disease that can
cause permanent joint damage and loss of function. Anti-tumor necrosis factor (antiTNF) agents inhibit the function of tumor necrosis factor (TNF), which leads to a
reduction in the progression of joint damage due to inflammation. However, an
increased risk of serious infections in RA patients using anti-TNF agents has been
observed in previous studies. This increased risk may be due to the immunologic
disturbance of the RA disease process itself, the immunosuppressive properties of
anti-rheumatic drug therapies, or co-existing risk factors for infection present in RA
patients. Herein, our aim is to assess potential predictors of hospitalized infection in
RA patients using anti-TNF agents.
Objective: Our objective is to determine if patients with RA who are prescribed the
anti-TNF agents; adalimumab, etanercept, or infliximab, are at an increased risk of
having a serious infection. In addition, we sought to identify potential predictors of an
increased risk of infection in RA patients using anti-TNF agents.
Methods: A nested case-control study was conducted using de-identified data from
the ClinformaticsTM DataMart (OptumInsight, Eden Prairie, MN), an administrative
health claims database from a large national private insurer. An initial cohort of
78,657 patients with ≥1 RA diagnosis was identified. Patients were included from this
initial cohort based on age, enrollment eligibility, number of RA diagnoses, exposure
to an anti-TNF agent, and excluded based on certain comorbidities. A final RA cohort
sample of 15,181 patients was formed. A follow-up period of 1 year was selected to
analyze serious infections requiring hospitalization; these events were identified with a

comprehensive set of ICD-9 codes for serious infections requiring inpatient admission.
Patients were classified as cases if they experienced a serious infection during the 1year follow up. The final selected cases and controls were matched on a 1:1 ratio
based on gender, region, and RA cohort entry date (quarter, year). A total of 155 cases
and 155 controls were identified. Both univariable and multivariable conditional
logistic regression models were built to produce a final multivariable predictive
model.
Results: Among, RA patients using anti-TNF agents, those with recent prednisone use
were 1.873 times more likely to have a hospitalized infection (95% confidence interval
[CI] 1.015-3.458). Patients with comorbid diabetes were 2.963 times more likely to
experience a hospitalized infection (95% CI 1.445-6.078) and patients with comorbid
chronic obstructive pulmonary disease (COPD) were 9.233 times more likely to
experience a hospitalized infection (95% CI 2.755-30.947). Lastly, patients with a
previous history of infection were 8.984 times more likely to have a hospitalized
infection (95% CI 1.895-42.595). No associations between anti-TNF agent
(adalimumab, infliximab, or etanercept) or incident/prevalent anti-TNF use and
hospitalized infection were observed.
Conclusion: The use of specific anti-TNF agents was not independently associated
with an increased risk of hospitalized infection in RA patients. Predictors associated
with hospitalized infection in RA patients using anti-TNF agents included recent
prednisone use, comorbid diabetes, comorbid COPD, and previous history of
infection.
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CHAPTER 1

INTRODUCTION

Rheumatoid arthritis (RA) is an autoimmune disease characterized by the chronic
inflammation of synovial joints causing persistent pain and stiffness that can
eventually result in joint deformities and loss of function.1 Given the debilitating
nature of RA, the disease poses a significant negative impact on health-related quality
of life.2,3 In 2005, an estimated 1.3 million (0.6%) adults had RA in the United States
(US).4 There is no cure available for RA, but the condition can be managed to slow
down the progression of disease and improve a patient’s quality of life. Current
treatment options for RA include non-steroidal anti-inflammatory drugs (NSAIDs),
traditional disease-modifying anti-rheumatic drugs (DMARDs), and biologic
DMARDs. The type of treatment used depends on a patient’s disease activity, signs
and symptoms, and prognosis. The current treatment model for RA focuses on an
early, aggressive combination therapy approach by prescribing a combination of
multiple drugs early on in order to achieve adequate disease control as quickly as
possible.5
Biologic DMARDs, particularly anti-tumor necrosis factor (anti-TNF) drugs have
emerged as important agents in the treatment of RA, especially in patients who have
failed to respond to traditional DMARDs alone. Anti-TNF medications approved by
the US Food and Drug Administration (FDA) for a number of conditions including
rheumatoid arthritis, juvenile idiopathic arthritis, Crohn’s disease, ulcerative colitis,
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psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.6 The introduction of
anti-TNF drugs beginning in the late 1990s revolutionized the treatment of rheumatoid
arthritis (RA) as they have been shown to be very effective at reducing inflammation
in RA patients.7-9
Tumor necrosis factor (TNF) plays an important role in host cell defense as a proinflammatory cytokine involved in systemic inflammation.10 This inflammatory
response against harmful bacteria and viruses is controlled and regulated by the body
under normal conditions. In patients with RA, macrophages overproduce TNF leading
to inflammation of the joints. Anti-TNF agents inhibit the function of TNF by
preventing TNF from binding to its receptor, which reduces the progression of joint
damage due to inflammation.10,11
An uncommon, yet significant side effect associated with anti-TNF drug use is
the increased risk of serious infections.12,14-16 The prescribing information for the antiTNF agents; adalimumab, etanercept, and infliximab contains black box warnings
ordered by the FDA indicating the increased risk of serious infection leading to
hospitalization or death and recommending discontinued use if a patient develops a
serious infection.17-19 This increased risk of infection may be due to the immunologic
disturbance of the RA disease process, the immunosuppressive properties of antirheumatic drug therapies, or co-existing risk factors for infection present in RA
patients. Most likely, this increased risk of infection is due to a combination of these
different factors.12-15
A retrospective longitudinal cohort study published by Doran et al20 in 2002
compared infection rates in a group of patients with RA with those in a group of
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individuals without RA. The study reported results from a cohort of Rochester,
Minnesota residents who were first diagnosed as having RA between 1955 and 1994.
Study subjects were followed until death, migration from the area, or study end
(January 1, 2000), whichever came first. Among 609 patients with incident RA in
1955-1994, 290 (47.6%) experienced ≥1 serious infection. Infections requiring
hospitalization were significantly more frequent in RA patients (9.57/100 personyears) than in non-RA study subjects (5.09/100 person-years) with a rate ratio of 1.88
(95% confidence interval [CI] 1.71-2.07). In other words, the researchers found that
the risk of developing a serious infection requiring hospitalization in patients with RA
was estimated to be nearly two-fold in comparison with non-RA patients. As this
study occurred before anti-TNF agents were widely available for the treatment of RA,
the increased risk of infection in RA patients was well established before the
introduction of anti-TNF agents to the RA drug market.
Research to better understand the risk factors associated with the increased rate of
hospitalized infection in RA patients using anti-TNF agents remains limited,
particularly among patient populations within the US. The lack of studies focusing on
risk factors establishes a need for further research to identify potential predictors of
hospitalized infection in this patient population using medications which can increase
their risk of infection.
Therefore, the objective of this study was to determine whether specific anti-TNF
agents, adalimumab, etanercept, or infliximab, increased the risk of hospitalized
infection. A secondary objective was to identify potential predictors for hospitalized
infection in RA patients using anti-TNF agents. These findings will help inform
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clinicians and patients about factors that may affect the development of serious
infections.
The hypothesis for this study is that the odds of hospitalized infection among RA
patients using anti-TNF agents will be greater in patients with older ages,
corticosteroid use, disease modifying anti-rheumatic drug (DMARD) use, and
comorbidities such as diabetes mellitus, chronic kidney disease, and chronic
obstructive pulmonary disorder.
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CHAPTER 2

REVIEW OF LITERATURE

Although numerous studies have explored the association between anti-TNF use
and an increased risk of infection, fewer studies in comparison have focused on
identifying additional potential predictors of hospitalized infection in RA patients
treated with these medications.
Studies were eligible for inclusion into the literature review based on several
broad criteria. We searched for studies using PubMed, the Cochrane databases, and
Google Scholar and identified studies published from 2007 to 2013. First, the
reviewed studies had to have a study cohort comprised of only RA patients defined as
having ≥1 RA diagnosis. Second, exposures of interest had to include the anti-TNF
agents, adalimumab, etanercept, and infliximab. Studies that evaluated newer antiTNF agents such as golimumab and certolizumab pegol were not included into our
literature review. And lastly, the outcome of interest had to include, but was not
limited to serious infection requiring hospitalization. Appendix 1 lists the selected
studies with further details on study design, patient population, inclusion and
exclusion criteria, exposure and outcome, and significant predictors.
A retrospective cohort study by Curtis et al12 published in 2007 used data from
the medical and pharmacy administrative claims of a large US health care
organization. The objective of this study was to evaluate the risk of serious bacterial
infections in RA patients using anti-TNF agents and traditional DMARDs alone.
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Researchers found that the adjusted hazard ratio (HR) of hospitalized bacterial
infection among patients who received anti-TNF drugs was 1.9 (95% confidence
interval [CI] 1.3–2.8) compared with patients who received methotrexate only. In
other words, the risk of hospitalized bacterial infection was approximately 2-fold
higher among patients receiving anti-TNF agents versus patients receiving
methotrexate alone. Significant predictors of infection included anti-TNF use, older
age, number of physician visits, prior infection, concomitant prednisone use, and
presence of comorbidities, including chronic obstructive pulmonary disease/asthma,
diabetes mellitus, and kidney disease.
A retrospective cohort study by Favalli et al21 published in 2009 used data from
the regional population-based Lombardy Rheumatology Network (LORHEN) registry
consisting of RA patients using anti-TNF agents from four major Rheumatology Units
in Lombardy, Italy. The objective of the study was to estimate the incidence of serious
infections in the patients treated with anti-TNF agents and identify significant
predictors of infection. The researchers found that 6.9% of patients in the eligible
cohort experienced a serious infection requiring hospitalization and/or intravenous
antibiotic therapy with an overall incidence rate of 3.59/100 patient-years (95% CI
2.77–4.41). Significant predictors of infection included age (per 1 year), concomitant
prednisone use, and erythrocyte sedimentation rate (ESR).
A retrospective cohort study by Atzeni et al22 published in 2012 used data from
the nationwide Gruppo Italiano Studio Early Arthritis (GISEA) registry, which
registers and monitors rheumatic patients treated with biological drugs at hospital and
community-based rheumatology units throughout Italy. The objective of the study was
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to assess the risk of serious infections in RA patients using anti-TNF therapy and
identify potential risk factors. The researchers found that 6.36% of patients over a
follow-up time of 9 years in the eligible cohort experienced a serious infection
requiring hospitalization or intravenous antibiotic therapy with an overall incidence
rate of 3.18/100 patient-years (95% CI 2.52–3.83). Significant predictors of infection
included corticosteroid therapy, concomitant DMARD therapy, and age at the start of
anti-TNF treatment.
A nested case-control study by Widdifield et al23 published in 2013 used data
from the Ontario Health Insurance Plan (OHIP) Database, an administrative claims
database comprised of patients in Ontario, Canada. The objective of the study was to
identify the risk of infection in a cohort of seniors with RA using anti-TNF agents in
the OHIP database and identify potential risk factors for infection. The researchers
found that 23.91% of patients over a follow-up time of 12 years in the eligible cohort
experienced a serious infection requiring hospitalization or an ER visit for an
incidence rate of 4.64 events/100 patient years (95% CI not reported). Significant
predictors of infection included rural residence, diabetes mellitus, chronic lung
disease, renal disease, glucocorticoid use ≤5 mg/day, glucocorticoid use ≥20 mg/day,
methotrexate use ≤10 mg/day, methotrexate use >10 mg/day, anti-TNF use, extra
articular features of RA, joint replacements, and history of previous infection.
A retrospective cohort study by van Dartel24 et al published in 2013 used data
from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. The objective of
the study was to identify predictors of the increased risk of serious infections in RA
patients treated with anti-TNF agents. Researchers found that 6.3% of patients over a
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follow-up time of 5 years in the eligible cohort developed a serious infection requiring
hospitalization and/or intravenous antibiotic therapy. The incidence rate in the first
year after the initiation of anti-TNF therapy was 4.57/100 patient-years and 2.91/100
patient-years over 5 years (95% CI not reported). Significant predictors of infection
included older age, corticosteroid use, visual analogue scale (VAS) pain, Health
Assessment Questionnaire (HAQ), tender joint count 28 joints (TJC28), and presence
of comorbidities.
From a review of the literature, the majority of studies that investigate possible
risk factors for infection in RA patients using anti-TNF agents have been performed
using data from rheumatic disease registries and healthcare databases from outside of
the United States. The one US study by Curtis et al12, included patients with and
without anti-TNF use. Significant predictors of infection that were common across the
studies reviewed included increased age, corticosteroid use, DMARD use, and
presence of comorbidities such as diabetes, chronic kidney disease, and chronic
obstructive pulmonary disorder (COPD).
The objective of this study was to assess risk factors for serious infections
requiring hospitalization in RA patients using anti-TNF agents. This study will
provide clinicians and RA patients with more knowledge on which factors are
predictive of an increased risk of infection which may help reduce and prevent such
infections. Furthermore, the use of a large, national administrative claims database
representative of the privately insured population in the United States will produce
more generalizable results on potential risk factors for infection among patients with
RA in the United States.
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CHAPTER 3

METHODOLOGY

Study Design and RA Cohort Definition
A nested case-control study was conducted using data from the ClinformaticsTM
DataMart (OptumInsight, Eden Prairie, MN), an administrative health claims database
from a large national private insurer. The database contains de-identified patient level
data across multiple categories including medical claims, pharmacy claims, and
administrative data. We selected a nested case-control design because it is efficient for
the study of rare outcomes and good for assessing multiple exposures. The outcome of
interest in this study, hospitalized infection, is relatively rare with rates of infection
ranging from 6-7% during extended follow-up time periods.22,24 Data from the study
time period of January 1, 2010 to December 31, 2013 was used in the analyses.
For inclusion into the RA cohort, both cases and controls had to be 18 to 63 years
old at the time of their entry into the RA cohort (for a timeline of the RA cohort,
please see Figure 1). Both cases and controls had to have ≥2 RA diagnoses
(International Classification of Diseases, Ninth Revision, Clinical Modification [ICD9-CM] code for RA of 714.x) separated by >7 days and occurring within 1 year of
each other. Patients also had to have continuous enrollment for ≥2 years. More
specifically, patients had to be continuously enrolled for the 12-months before the first
RA diagnosis and the 12-months after the first RA diagnosis. The RA cohort entry
date is defined as the date of the first RA diagnosis in which all the predefined RA
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cohort criteria were met. The reasoning for requiring continuous enrollment in the 12months prior to the first RA diagnosis is to establish a look-back period for the
assessment of covariates such as a previous history of infection. Patients were
followed starting from the cohort entry date until 12-months or until the outcome of
interest occurred, whichever event came first.
Lastly, both cases and controls were required to have ≥1 medical or prescription
claim for an anti-TNF agent (adalimumab, etanercept, or infliximab) occurring after
the RA cohort entry date and before the outcome of interest. This inclusion criteria
was applied in order to increase our specificity of RA case ascertainment and to
establish temporality that both cases and controls were exposed to an anti-TNF agent
prior to the outcome of interest (hospitalized infection). As controls do not experience
the outcome of interest, each matched control was assigned the same index date
(defined as the date of the first hospitalized infection in cases) as its matched case.
Further details on identification of cases and controls are presented in the next section.
Patients were excluded for loss of coverage or inpatient death occurring ≤12
months after the cohort entry date. Patients were also excluded if they had a diagnosis
±12-months of the cohort entry date for another condition for which adalimumab,
etanercept, and infliximab are approved, including Crohn’s disease, ulcerative colitis,
psoriatic arthritis, plaque psoriasis, or ankylosing spondylitis.25 Patients were also
excluded if they had a diagnosis ± 12-months of the cohort entry date for malignant
neoplasm26 (for ICD-9-CM codes of exclusion criteria, see Appendix 2). The
previously mentioned exclusion criteria for comorbidities was introduced to increase
the homogeneity of the sample because RA patients with other autoimmune and
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inflammatory conditions may have different infection risk profiles and infectionrelated risk factors.
Identification of Cases and Controls
Cases and controls were derived from the aforementioned RA cohort (for a
timeline of the nested case-control design, please see Figure 2). Cases were defined as
patients who had an inpatient hospital admission code in any position for infection in
the 12-months following the cohort entry date. The outcome of interest for cases was
restricted to only the earliest hospitalized infection. Outcome events were identified
using a comprehensive set of ICD-9 codes developed as part of a systematic literature
review and two validation studies to identify serious infections in RA patients (for
ICD-9-CM codes, see Appendix 3). This particular infection algorithm has
demonstrated positive predictive values of ≥80%.27 For each case, an index date was
assigned corresponding to the date of the inpatient hospital admission.
Controls included those not experiencing a hospitalized infection in the 12months following the cohort entry date. Controls were randomly matched (without
replacement) to cases on a 1:1 ratio based on gender, geographic region, and cohort
entry date (quarter, year). Since the controls do not experience the outcome of interest,
hospitalized infection, each matched control was assigned the same index date as its
matched case.
Drug Exposure Determination and Potential Predictors
Cases and controls were considered exposed to an anti-TNF agent if they had ≥1
pharmacy or medical claim for adalimumab, etanercept, or infliximab in the 90-days
prior to the index date. Patients could be exposed to ≥1 anti-TNF agent during this 90-
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day exposure risk window. The self-injectable drugs adalimumab and etanercept were
identified based on pharmacy claims for prescription fills (see Appendix 4).
Adalimumab and etanercept were also identified based on medical claims considering
the fact that when adalimumab and etanercept are first prescribed to a patient, the first
injection is administered as part of a training session for the patient in an office setting
under the supervision of a health care professional.17,18 The exposure risk window for
adalimumab and etanercept will need to capture the possibility of the first dose being
administered in the office in addition to prescription fills. The infused drug infliximab
was identified based on medical claims, specifically the common procedure codes
(CPT) 96413 and 96415 for the 1st and 2nd hour of infusion, respectively.28
Potential predictors were selected based on general risk factors associated with
the etiology of RA and the relevant published literature12,21-24. Although previous
studies have shown an increased risk of infection correlated with disease severity
measures such as disease activity score 28 (DAS28), health assessment questionnaire
(HAQ), and visual analogue scale (VAS), these measures of disease activity were not
available from the ClinformaticsTM DataMart (OptumInsight, Eden Prairie, MN).
Gender and geographic region (Northeast, Midwest, South, and West) were selected as
matching variables, therefore they were not assessed as risk factors. To ascertain
potential predictors of hospitalized infection in RA patients using anti-TNF drugs, the
following covariates were collected for each case and control:


Age



Number of rheumatologist visits from RA cohort entry date to index date
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Previous infection: hospitalized infection occurring ≤12-months prior to the RA
cohort entry date



Joint replacement ≤360 days prior to index date



Exposure to specific anti-TNF medications: adalimumab, etanercept, and/or
infliximab, ≤90 days prior to index date



Exposure to disease modifying anti-rheumatic drugs (DMARDs), or
corticosteroids: methotrexate, azathioprine, leflunomide, hydroxychloroquine,
sulfasalazine, prednisone, ≤90 days prior to index date



Comorbidities: diabetes, chronic kidney disease (CKD), obstructive pulmonary
disorder (COPD), ≤90 days prior to index date



Prevalent or incident user of anti-TNF drug:
o Prevalent (new) user: ≥1 claim for exposed anti-TNF drug(s) occurring
between cohort entry date and 90-day exposure period
o Incident (continuing) user: 0 claims for exposed anti-TNF drug(s) occurring
between cohort entry date and 90-day exposure period

Statistical Analysis
Differences in the distribution of covariates among cases and controls was
assessed using Chi-squared tests for categorical variables and two-sample t-tests for
continuous variables. Conditional logistic regression was performed to assess the
relationship between the dependent variable, the first hospitalized infection, with the
independent risk factors described above. Multivariable conditional logistic regression
was performed with inclusion of variables with a p-value ≤0.20 in the univariable
models. A manual, backward, step-wise elimination was carried out to remove
13

variables with a Wald p-value >0.05 to produce a final multivariable model of
variables significantly associated with the dependent variable. To determine goodness
of fit, Akaike information criteria (AIC) values were compared between competing
models and a Hosmer-Lemeshow test was used to assess the final model fit.
Collinearity was assessed in the final model to determine if any of the independent
variables were highly correlated with one another. A variance inflation factor (VIF)
≥10 and/or a tolerance (TOL) value ≤0.10 would indicate variables with possible
collinearity.29 The odds ratios (OR) for hospitalized infection risk for each risk factor
was calculated with 95% confidence intervals and a p-value <0.05 was considered
statistically significant. Statistical analyses were performed using SAS® Version 9.4.
(Cary, NC).
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CHAPTER 4

FINDINGS

Study Population Characteristics
There were 176,745 patients initially identified as having ≥1 RA diagnosis during
the study time frame of January 1, 2010 to December 31, 2013 (for study population
flow chart, see Figure 3). All RA patients initially identified were age 18-63 years old.
All RA patients initially identified also had ≥2 RA diagnoses separated by >7 days and
occurring within 1 year of each other. Therefore, no patients were excluded based on
inclusion criteria involving age or RA diagnoses. We then excluded patients who did
not have continuous enrollment in the 12-months before their first RA diagnosis and
the 12-months after their first RA diagnosis (N=97,752). Next, patients with a
diagnosis ± 12-months of the RA cohort entry date for Crohn’s disease, ulcerative
colitis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, or malignant
neoplasm were excluded (N=336). We then excluded patients without ≥1 prescription
or medical claim for an anti-TNF agent occurring in the 12-months after the RA
cohort entry date (n=63,476) resulting in a final eligible RA cohort of 15,181 patients.
Next, we identified cases as the patients who experienced a hospitalized infection
occurring between the patient’s RA cohort entry date and the end of the 1-year follow
up period. A total of 255 eligible cases was identified. Next, we excluded eligible
cases and controls who did not have ≥1 prescription or medical claim for an anti-TNF
agent occurring between the RA cohort entry date and the index date (n=965). After
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all inclusion and exclusion criteria were applied, one control was matched to each case
according to the matching variables gender, region, and cohort entry date (quarter,
year). We were able to identify 155 cases matched on a 1:1 ratio to 155 controls.
The demographic and clinical characteristics of cases and control are presented in
Table 1. Cases and controls did not differ significantly in regards to age (p=0.6877)
with both cases and controls having a mean age of approximately 45 years old. The
majority of cases (56.13%) and controls (62.58%) had ≥2 rheumatologist visits
between their RA cohort entry date and their index date, and this difference was not
statistically significant (p=0.5048). Both cases and controls were mostly female
(75.48%) and from the South (50.32%). Adalimumab use (p=0.6556) and infliximab
use (p=0.4030) did not differ significantly between cases and controls. However,
etanercept use differed significantly between cases and controls (15.48% cases,
25.81% controls; p=0.0248). Prednisone use was significantly higher in cases
compared with controls (31.61% cases, 21.29% controls; p=0.0394). Cases had a
significantly higher frequency of comorbid conditions including diabetes (30.32%
cases, 10.97% controls; p=<0.0001) and COPD (25.16% cases, 3.23% controls;
p=<0.0001). Cases also experienced a significantly higher frequency of previous
infection compared with controls (10.97% cases, 1.29% controls; p=0.0004).
Univariable Analysis
In univariable logistic regression, we identified covariates having a statistically
significant association with the occurrence of hospitalized infection. Results of the
univariable analysis of potential risk factors are presented in Table 2. Covariates with
a p-value ≤0.20 were considered for building multivariable models. Based on
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univariable comparison of cases and controls; age, etanercept use, methotrexate use,
prednisone use, comorbid diabetes, comorbid chronic kidney disease, comorbid
COPD, joint replacement, and previous history of infection were considered for the
multivariable model.
Univariable analysis of incident user and prevalent user of anti-TNF agents was
not statistically significant (p=0.3551). However, the covariate, incident user, was
forced into the initial multivariate model to assess whether incident user could be used
to create an interaction term with etanercept use in the event that both main effects
were statistically significant in multivariable analysis. A significant interaction
between incident user and etanercept use would indicate that there is evidence that
hospitalized infection in patients using etanercept is related to whether the patient is an
incident user of etanercept.
Multivariable Analysis
Multivariable conditional logistic regression models were built to examine the
association between anti-TNF drug use and the occurrence of serious infection
requiring hospitalization. Results of the final model are presented in Table 3.
RA patients with recent prednisone use were 1.873 times more likely to have a
hospitalized infection (95% CI 1.015-3.458). Patients with comorbid diabetes were
2.963 times more likely to experience a hospitalized infection (95% CI 1.445-6.078)
and patients with comorbid COPD were 9.233 times more likely to experience a
hospitalized infection (95% CI 2.755-30.947). Lastly, patients with a previous history
of infection were 8.984 times more likely to have a hospitalized infection (95% CI
1.895-42.595).
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Collinearity was assessed in the final model to determine if any of the
independent variables were highly correlated with one another. The variance inflation
factors (VIF) were all well under 10 and the tolerance (TOL) values were all greater
than 0.10. Therefore, there was no evidence of collinearity based on VIF and TOL.
Lastly, a Hosmer-Lemeshow test was performed on the final model to determine if the
model was an adequate fit for the data. The Hosmer-Lemeshow test produced a pvalue of 0.6925, which is greater than 0.05. Therefore, there was no evidence that our
model fits inadequately based on this test.
Discussion
Anti-TNF agents are effective for the treatment of RA, but may increase the risk
for serious infections. The FDA requires manufacturers of anti-TNF agents to include
black box warnings alerting health care professionals and patients of the risk of serious
infections leading to hospitalization or death when using anti-TNF agents.17-19 A
number of randomized clinical trials have demonstrated this increased risk. In a metaanalysis of 44 randomized, double-blind, controlled trials of patients with RA that
evaluated anti-TNF use, anti-TNF agents as a group was associated with a higher risk
of serious infection (Odds ratio [OR] 1.42, 95% confidence interval [CI] 1.13-1.78)
compared with placebo and traditional disease-modifying anti-rheumatic drug
treatments (DMARDs).30
Based on previous studies in other patient populations, we hypothesized that in
RA patients using anti-TNF agents, the odds of hospitalized infection would be greater
in patients with older ages, corticosteroid use, disease modifying anti-rheumatic drug
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(DMARD) use, and comorbidities such as diabetes mellitus, chronic kidney disease,
and chronic obstructive pulmonary disorder (COPD).
We assessed the association between anti-TNF use in RA patients and the
increased risk of hospitalized infections in a large national privately insured
population. Significant predictors of hospitalized infection in RA patients using antiTNF agents were prednisone use, comorbid diabetes, comorbid COPD, and previous
history of infection.
In relation to existing research, our findings are in agreement with studies that
report an increased risk of serious infections in RA patients with prednisone use,
diabetes, COPD, and previous history of infection.
In a retrospective cohort study by Favalli et al21 to assess the incidence of serious
infection in patients treated with anti-TNF agents, significant predictors of an
increased risk of infection included prednisone use (Hazard ratio [HR] 2.89, 95% CI
1.12–7.48). Similarly, Atzeni et al22 conducted a retrospective cohort study to evaluate
the risk of serious infection in RA patients using anti-TNF agents and also found that
the use of corticosteroids (HR 1.63, 95% CI 1.01-2.64) was a significant predictor of
an increased risk of infection. In a nested case-control conducted by Widdifield et al23
comparing senior RA patients with incident serious infection to matched controls,
significant predictors of an increased risk of infection were chronic lung disease (OR
1.31, 95% CI 1.25-1.36), previous history of infection (OR 1.51, 95% CI 1.45-1.57),
and prednisone use (OR 3.96 at low doses, 95% CI 3.67-4.27; OR 7.57 at high doses,
95% CI 6.87-8.34). In a retrospective cohort study by van Dartel et al24 to identify
potential predictors of an increased risk of infection in RA patients using anti-TNF
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agents, significant predictors of an increased risk of infection were corticosteroid use
(HR 1.54, 95% CI 1.08-2.20) and the presence of comorbidities (diabetes, COPD, and
cardiovascular disease were assessed as a single variable) (HR 1.31, 95% CI 0.981.175).
We did not identify an independent association between the increased risk of
hospitalized infection and the use of specific anti-TNF agents. There is not a
consistent consensus as to whether the risk of serious infections differs between
adalimumab, etanercept, and infliximab with earlier studies reporting conflicting
results. In studies that have assessed potential differences in risk between anti-TNF
agents, Favalli et al21 reported no statistically significant difference in risk between
adalimumab, etanercept, or infliximab. On the contrary, Atzeni et al22 demonstrated
that the use of infliximab (HR 4.20, 95% CI 2.71-8.91) or adalimumab (HR 2.22, 95%
CI 1.12-4.42) when compared to the use of etanercept were strong and significant
predictors of infection.
Demographic and patient characteristics unique to our RA cohort, as well as other
limitations of the study design may be contributing factors as to why our results
differed from previous studies. In regards to increased age as a potential predictor, we
were unable to find an association between an increased risk of serious infection and
older age. Previous studies that evaluated age as a continuous variable like our study
have shown patients with increased age are at a higher risk of serious infection with an
adjusted hazard ratio of approximately 1.03.21,22 Another study that evaluated age as a
categorical variable showed patients >65 years old were at an approximately two-fold
higher risk of experiencing a serious infection compared to patients <55 years old.24 A
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potential reason as to why we were unable to find an association between the
occurrence of serious infection and increased age may be attributed to the younger and
narrower age range of our study sample, which only included patients aged 44-48 with
an average age of approximately 45 years old in both our case and control groups.
Although our final eligible RA cohort was relatively large, a fairly small number
of hospitalized infection events (1.7%) were identified resulting in a smaller sample
size for our nested case-control design. Our smaller sample size contributed to wide
confidence intervals of the effect estimates from our final multivariable model and
may have limited our power to detect an association between anti-TNF use and
additional potential predictors. If we were able to identify a substantially larger sample
size, we could have potentially identified more predictors, but the strength of the
association related to many additional predictors may be weaker. Our study was able
to identify strong and significant predictors of infection, particularly in patients with
comorbid COPD and previous history of infection despite our small sample size and
resultant wide confidence intervals.
In addition, the nested case-control design means that causality cannot be
explicitly inferred between anti-TNF use and hospitalized infection as not all relevant
risk factors are captured and recorded within the dataset. Therefore, it is not possible
to measure and control for all factors that may have influenced the occurrence of
hospitalized infection.
Furthermore, previous studies have found measures of RA disease severity to be
significant predictors of hospitalized infection in patients using anti-TNF drugs.
However, the ClinformaticsTM DataMart does not directly capture indicators of disease

21

severity. We included proxies of disease severity as potential predictors in our
analyses, such as the number of rheumatologist clinic visits from RA cohort entry date
to index date, prednisone use, and presence of comorbidities. In addition, there is no
evidence that confounding by indication is a concern according to the type of antiTNF agent. The 2015 American College of Rheumatology (ACR) recommendations
do not indicate a particular order of preference when prescribing an anti-TNF agent to
a patient based on disease severity.31 Future research may be directed towards further
analyses using disease risk scores as a stronger proxy for disease severity.
Strengths of our study include the use of validated ICD-9 codes with proven high
positive predictive values for disease to identify cases of hospitalized infection in
administrative data, which may reduce potential misclassification bias. In addition, the
use of a large privately insured population allows for more generalizable results for
RA patients using anti-TNF agents in the US as opposed to studies that use data
sources outside of the US. However, this also means that the results cannot be
extrapolated towards patient populations beyond the privately insured. Furthermore,
our results are not representative of older patient populations like those represented in
Medicare. Our results are only generalizable to a population representative of our final
patient sample such as being predominantly female, younger, from the South, and
privately insured RA patients in the United States when most previous studies have
analyzed populations outside of the US.
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CHAPTER 5

CONCLUSION

Anti-TNF agents are known to inhibit the function of tumor necrosis factor,
which can lead to a reduction of joint damage and inflammation in RA patients using
these agents. However, serious infections have been reported in patients using antiTNF drugs.
In our patient cohort, we were unable to identify a significant association between
the increased risk of hospitalized infection and specific anti-TNF use in RA patients.
Significant predictors of hospitalized infection in RA patients using anti-TNF agents
included recent prednisone use, diabetes, COPD, and previous history of infection.
The impact of these findings suggest that careful monitoring of these specific patient
populations may be important in reducing the occurrence of hospitalized infection
among patients using anti-TNF agents.
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TABLES
TABLE 1: Demographic and clinical characteristics of RA patients – cases and
controls (N=310)
Variable

Cases
n=155
Frequency (%)

Controls
n=155
Frequency (%)

p-value

45.51 ± 1.13

45.56 ± 1.13

0.6877

Male gender

38 (24.52)

38 (24.52)

1.0000

Number of rheumatologist visits from RA
cohort entry date to index date:
0 visit

28 (18.06)

23 (14.84)

0.5048

1 visit

40 (25.81)

35 (22.58)

≥ 2 visits

87 (56.13)

97 (62.58)

Northeast

9 (5.81)

9 (5.81)

Midwest

39 (25.16)

39 (25.16)

South

78 (50.32)

78 (50.32)

West

29 (18.71)

29 (18.71)

26 (16.77)

29 (18.71)

0.6556

Etanercept

24 (15.48)

40 (25.81)

0.0248

Infliximab

57 (36.77)

50 (32.26)

0.4030

38 (24.52)

51 (32.90)

0.1027

49 (31.61)

33 (21.29)

0.0394

Azathioprine

1 (0.65)

2 (1.29)

0.5618

Leflunomide

5 (3.23)

5 (3.23)

1.0000

17 (10.97)

15 (9.68)

0.7089

5 (3.23)

8 (2.58)

0.3953

47 (30.32)

17 (10.97)

<.0001

10 (6.45)

5 (3.23)

0.1857

39 (25.16)

5 (3.23)

<.0001

Age, mean ± SD

Region:

Anti-TNF drug exposure 90 days prior to
index date
Adalimumab

Other drug exposure 90 days prior to
index date
Methotrexate
Prednisone

Hydroxychloroquine
Sulfasalazine

1.0000

Comorbidities
Diabetes mellitus
(90 days prior to index date)
Chronic kidney disease
(90 days prior to index date)
Chronic obstructive pulmonary
disorder
(90 days prior to index date)
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TABLE 1 (continued): Demographic and clinical characteristics of RA patients –
cases and controls (N=310)
Variable

Cases
n=155
Frequency (%)

Controls
n=155
Frequency (%)

p-value

Joint replacement
(360 days prior to index date)
Previous history of infection
(hospitalized infection 12 months prior to
cohort entry date)
Prevalent or incident user of anti-TNF drug

7 (4.52)

2 (1.29)

0.0908

17 (10.97)

2 (1.29)

0.0004

82 (52.90)

75 (48.39)

0.4265

73 (47.10)

80 (51.61)

0.4265

Incident
(0 claims for exposed anti-TNF drug(s)
between cohort entry date and 90-day
exposure period)
Prevalent
(≥1 claim for exposed anti-TNF drug(s)
between cohort entry date and 90-day
exposure period)
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TABLE 2: Univariable logistic regression analysis of covariates
Variable

Univariable Model
Odds Ratio

95% Confidence
Interval (CI)

Unadjusted
p-value

Age

0.111

0.014-0.877

0.0371

Number of rheumatologist visits from RA
cohort entry date to index date (ref=0)
1 visit

1.063

0.487-2.321

0.8783

0.695

0.365-1.323

0.2682

0.870

0.478-1.583

0.6476

Etanercept

0.500

0.274-0.911

0.0236

Infliximab

1.269

0.759-2.122

0.3633

0.658

0.397-1.090

0.1040

Prednisone

1.640

0.997-2.697

0.0512

Azathioprine

0.500

0.045-5.514

0.5714

Leflunomide

1.000

0.290-3.454

1.0000

Hydroxychloroquine

1.167

0.540-2.522

0.6952

Sulfasalazine

0.625

0.204-1.910

0.4097

3.308

1.779-6.151

0.0002

2.250

0.693-7.306

0.1772

12.333

3.803-40.000

<.0001

3.500

0.727-16.848

0.1182

8.500

1.964-36.790

0.0042

0.781

0.463-1.318

0.3551

1.280

0.759-2.160

0.3551

≥ 2 visits
Anti-TNF drug exposure 90 days prior to
index date
Adalimumab

Other drug exposure 90 days prior to
index date
Methotrexate

Comorbidities
Diabetes mellitus
(90 days prior to index date)
Chronic kidney disease
(90 days prior to index date)
Chronic obstructive pulmonary
disorder
(90 days prior to index date)
Joint replacement
(360 days prior to index date)
Previous history of infection
(hospitalized infection 12-months prior
to cohort entry date)
Prevalent or incident user of anti-TNF
drug
Prevalent
(≥1 claim for exposed anti-TNF
drug(s) between cohort entry date
and 90-day exposure period)
Incident
(0 claims for exposed anti-TNF
drug(s) between cohort entry date
and 90-day exposure period)
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TABLE 3: Final multivariable logistic regression analysis of covariates with manual,
backward, step-wise elimination to remove variables with a P-value >0.05
Variable

Multivariate Model
Odds Ratio

95% Confidence
Interval (CI)

Adjusted
p-value

1.873

1.015-3.458

0.0447

2.963

1.445-6.078

0.0030

9.233

2.755-30.947

0.0003

8.984

1.895-42.595

0.0057

Other drug exposure 90 days prior to
index date
Prednisone
Comorbidities
Diabetes mellitus
(90 days prior to index date)
Chronic obstructive pulmonary
disorder
(90 days prior to index date)
Previous history of infection
(hospitalized infection 12
months prior to cohort entry
date)
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FIGURES
FIGURE 1: Timeline of RA cohort

RA= rheumatoid arthritis
Anti-TNF = anti-tumor necrosis factor
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FIGURE 2: Timeline of nested case-control study
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FIGURE 3: Study sample selection flowchart

RA = rheumatoid arthritis
Anti-TNF = anti-tumor necrosis factor
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APPENDICES
APPENDIX 1: Literature review table
Author,
Year
Curtis et
al12,
2007

31

Design

Population

Retrospective
cohort

 Medical and
pharmacy
administrative
claims of
large US
health
organization
between
May 1998 and
December
2003

Inclusion/Exclusion
Criteria
Inclusion:
 ≥18 years old
 ≥2 RA diagnoses
 Each individual had to
have received an
infusion or filled
a prescription for an
anti-TNF drug or
filled at least 3
prescriptions for
methotrexate

Exposure/Outcome Definition

Significant Predictors

Follow up:
 Infections identified within 6
months of the most recent
exposure to the anti-TNF or
methotrexate
Exposure:
 Patients who received an antiTNF drug were the exposed
cohort and those who received
methotrexate only were the
unexposed/comparator cohort
 Date of 1st exposure to the antiTNF
Outcome:
 Identified hospitalizations that
occurred after index date with
≥2 ICD-9-CM codes for
bacterial infections (at least 1 of
these codes had to be based on a
face-to-face encounter with a
physician, additional ICD-9-CM
codes could originate from a
claim for a diagnostic test or
procedure)

Multivariate analysis:
 Anti-TNF treatment (HR 1.94, 95% CI
1.32–2.83)
 Age (5-year increments) (HR 1.14, 95%
CI 1.03–1.27)
 No. of face-to-face physician visits (HR
1.04, 95% CI 1.01–1.07)
 Prior infection (HR 1.46, 95% CI 0.85
2.51)
 Chronic obstructive pulmonary disease
or asthma (HR 1.90, 95% CI 1.19–3.04)
 Diabetes mellitus (HR 1.75, 95% CI
1.10–2.78)
 Kidney disease (HR 3.23, 95% CI 1.35–
7.73)
 Decubitus ulcer (HR 3.05, 95% CI
1.50–6.19)
 Mean prednisone dosage
- ≤5 mg/day (HR 1.49, 95% CI 0.82–
2.72
- 5–10 mg/day (HR 1.46, 95% CI 0.84–
2.54)
- ≥10 mg/day (HR 1.85, 95% CI 1.2–
2.85)

Author,
Year
Favalli et
al21,
2009

Design

Population

Retrospective
cohort

 Lombardy
(Italy)
Rheumatology
Network
(LORHEN)
registry (since
1999)
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Inclusion/Exclusion
Criteria
Inclusion:
 ≥1 diagnosis of RA
and ≥ 18 years old
 ≥1 infusion or filled a
prescription for
etanercept, infliximab,
or adalimumab
 All patients treated in
accordance with the
Italian Society of
Rheumatology
guidelines for the use
of anti-TNFα agents:
Failure to respond to
≥1 course of
combination therapy
with full-dose
traditional DMARDs,
one of which is
methotrexate unless
contraindicated and
disease Activity Score
on 28 joints (DAS28)
of >3.5
Exclusion:
 Active infection
and/or history of
malignancy or a premalignant condition,
class III/IV congestive
heart failure, or
demyelinating
disorders

Exposure/Outcome Definition

Significant Predictors

Follow up:
 Followed for 1st administered
anti-TNF agent until 36 months
or first infection outcome
Exposure:
 1st administered dose of
adalimumab, etanercept, or
infliximab
Outcome:
 Physician documented infection
episodes recorded in medical
charts or outpatient visits

Multivariate analysis:
 Age (per 1 year) (HR 1.03/year, CI
1.01–1.06)
 Prednisone daily dose > 5 mg (HR 2.89,
95% CI 1.12–7.48)
 Erythrocyte sedimentation rate (ESR)
(HR 1.02 per every mm/h increase, 95%
CI 1.00–1.03)

Author,
Year
Atzeni et
al22,
2012

Design

Population

Retrospective
cohort

 GISEA (Italy)
registry (since
2008)
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Inclusion/Exclusion
Criteria
Inclusion:
 ≥18 years
 RA diagnosis by
rheumatologist
 ≥1 infusion or filled a
prescription for
etanercept, infliximab,
or adalimumab
 All patients treated ≥6
months with anti-TNF
agent or had
discontinued anti-TNF
earlier due to infection
 All patients treated in
accordance with the
Italian Society of
Rheumatology
guidelines for the use
of anti-TNF agents:
- Failure to respond to
at least one course of
combination therapy
with full-dose
traditional DMARDs,
one of which is
methotrexate unless
contraindicated
- Disease Activity
Score on 28 joints
(DAS28) of >3.5

Exposure/Outcome Definition

Significant Predictors

Follow up:
 Followed for 1st administered
anti-TNF agent until first
infection outcome
Exposure:
 1st infusion of infliximab or
filled prescription for
adalimumab or etanercept
 If patients switched to 2nd antiTNF agent, only time and
adverse events of 1st agent used
in analysis
Outcome:
 Physician documented infection
episodes, occurrence of adverse
events captured every 6 months

Multivariate analysis:
 Corticosteroid therapy (OR 1.633, 95%
CI 1.01-2.644)
 Concomitant DMARD during anti-TNF
treatment (OR 2.14, 95% CI 1.283.595)
 Age at start of anti-TNF treatment (OR
1.036, 95% CI 1.02-1.053)
 Use of infliximab (OR 4.916, 95% CI
2.71-8.906) or adalimumab (OR 2.22,
95% CI 1.12-4.42) rather than
etanercept

Author,
Year
Widdifiel
d et al23,
2013

Design

Population

Nested casecontrol

 Ontario health
administrative
data
 April 1, 1992
to March 31,
2010 data
analysis

Inclusion/Exclusion
Criteria
Inclusion:
 ≥66 years
 ≥2 billing code
diagnoses of RA >60
days apart, but within
5 years
 ≥1 prescription for an
oral glucocorticoid, a
DMARD, or a
biologic agent
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Exposure/Outcome Definition

Significant Predictors

Follow up:
 Followed on date when all
inclusion/exclusion criteria were
met until outmigration, death, or
the end of the study (March 31,
2010)
Exposure:
 Oral glucocorticoid, DMARD,
or biologic ≤365 days before
index date
Outcome:
 Cases: Emergency department
visit or hospital admission with
primary diagnosis of infection
between the later of April 1,
1998, or cohort entry, and
March 1, 2010
 Controls: Cases matched on age
(±5 years), sex, and date of
cohort entry (±1 year) to 5
controls from the same RA
cohort

Multivariate analysis:
 Rural (ref. urban) (OR 1.51, 95% CI
1.44–1.58)
 Comorbidities
- Diabetes Mellitus (OR 0.97, 95% CI
0.93–1.01)
- Chronic lung disease (OR 1.31, 95%
CI 1.25–1.36)
- Renal disease (OR 1.26, 95% CI 1.181.36)
 Current glucocorticoid use (mg/day)
- ≤5 (OR 3.96, 95% CI 3.67–4.27)
- ≥20 (OR 7.57, 95% CI 6.87–8.34)
 Current methotrexate use (mg/day)
- ≤10 (OR 2.38, 95% CI 2.22–2.56)
- >10 (OR 2.97, 95% CI 1.90–4.64)
 Current anti-TNF use (OR 1.60, 95%
CI 1.19-2.15)
 Extra articular features of RA (OR 1.11,
95% CI 1.07–1.16)
 Joint replacements (OR 1.01, 95% CI
0.97–1.06)
 Previous infections (OR 1.51, 95% CI
1.45–1.57)

Author,
Year
van
Dartel et
al24,
2013
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Design

Population

Retrospective
cohort

 Dutch
Rheumatoid
Arthritis
Monitoring
(DREAM)
biologic
registry (since
2003)
 Radboud
University
Nijmegen
Medical
Centre
(RUNMC)
(before 2003)
 5-year data
analysis

Inclusion/Exclusion
Criteria
Inclusion:
 Using adalimumab,
infliximab or
etanercept as 1st antiTNF agent
Exclusion:
 Received anti-TNF
agent as part of a
clinical trial.

Anti-TNF = anti-tumor necrosis factor
CI = confidence interval
DMARD = disease modifying anti-rheumatic drug
HR = hazard ratio
OR = odds ratio
RA = rheumatoid arthritis

Exposure/Outcome Definition

Significant Predictors

Follow up:
 Followed for 1st administered
anti-TNF agent until 5 years of
observation time or at the end of
follow-up, or after stop of an
anti-TNF agent plus five times
the half-life, or after the
occurrence of the 1st serious
infection
 Patients who switched between
anti-TNF agents, the treatment
with the next anti-TNF
contributed to the observation
time if it started within five
times the half-life of the former
anti-TNF agent
Exposure:
 1st administered dose of
adalimumab, etanercept, or
infliximab
Outcome:
 FDA definition for serious
adverse event: hospitalization
and/or intravenous antibiotic
treatment, life threatening,
disabling daily activities

Multivariate analysis:
 Age (ref. <55)
- 55-65 (HR 1.07, 95% CI 0.66-1.74)
- >65 (HR 2.11, 95% CI 1.39-3.22)
 Corticosteroid use baseline (HR 1.54,
CI 1.08-2.20)
 Visual analogue scale (VAS) pain
baseline (HR 0.98, CI 0.98-1.00)
 Health Assessment Questionnaire
(HAQ) baseline (HR 1.57, CI 1.122.22)
 Tender joint count 28 joints (TJC28)
(HR 1.04, CI 1.01-1.06)
 Presence of comorbidities (HR 1.31, CI
0.98-1.75)

APPENDIX 2: ICD-9-CM codes to identify exclusion criteria diagnoses25,26
Diagnosis

ICD-9-CM Code

Crohn’s disease

555.0 555.1 555.2 555.9

Ulcerative colitis

556.0 556.1 556.2 556.3 556.4 556.5 556.6 556.8
556.9

Psoriatic arthritis

696.0

Plaque psoriasis

696.1

Ankylosing spondylitis

720.0

Malignant neoplasm

140.x 172.x 173.00, 173.09 173.10, 173.19 173.20
173.29 173.30 173.39 173.40 173.49 173.50 173.59
173.60 173.69 173.70 173.79 173.80 173.89 173.90
173.99 174.x 209.36 209.7x
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APPENDIX 3: ICD-9-CM codes to identify hospitalized infection27
Diagnosis

ICD-9-CM Code

Meningitis

003.21 036.0 049.0 091.81 094.2 098.82 320.xx

Encephalitis

036.1 323.x 094.81 130

Cellulitis

040.0 569.61 681.xx 682.x 785.4 035 608.4 681.xx 614.3
528.3 566 597.0

Endocarditis

036.42 093.2x 98.84 391.1 397.9 421.x 421.9 422.92

Pneumonia

003.22 481.0 482.xx 483.x 485.x 486.x 513.0

Pyelonephritis/urinary tract
infection
Septic arthritis

590.xx 599.0

Osteomyelitis

003.24 730.2x 526.4 730.2x 526.4 730.0x 730.1x 376.03

Bacteremia/septicemia

038.xx 041.xx 790.7

Upper respiratory tract infection
Abdominal abscess

34 381.5x 382.x 383.0x 383.1 383.9 461.x 462.x 463
465.x 466 464.0x 472.x 473.x 475 510 510.9
95.2 540.1 569.5 567.x 572 590.2 601.2 614.4 998.59

Brain abscess

324.x

Cholecystitis

574.x 575 576.1 575.1x 575.1 575.12 575.11

Prostate infections

98.32 98.12 131.03 601.x

Gastroenteritis
Infectious conjunctivitis

001 002 003 003.0 004 005 008 008.1 008.2 008.4 008.5
009.x
372.0x 77.9 32.81

Device-associated infections

996.6x

Local infections of skin and
subcutaneous tissue
Gangrene

686.1 686.8 686.9

Retropharyngeal abscess

478.21 478.24 478.22

003.23 056.71 711.9x 711.0x 098.5x

785.4
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APPENDIX 3 (continued): ICD-9-CM codes to identify hospitalized infection27
Diagnosis

ICD-9-CM Code

Breast abscess

611.0

Splenic abscess

289.59

Pyogenic granuloma

686.1

Post-traumatic wound infection

958.3

Postoperative wound infection

998.5

Infective myositis

40.81

Necrotizing fasciitis

728.86

38

APPENDIX 4: National drug codes (NDC) and Healthcare Common Procedure
Coding System (HCPCS) codes to identify pharmacy or medical claims for the selfinjectable drugs adalimumab and etanercept
Proprietary (NonProprietary) Name

11 Digit National Drug Code
(NDC)

Humira (adalimumab)

00074006702
00074024302
00074024371
00074055401
00074055402
00074055404
00074055406
00074055471
00074055473
00074055474
00074254001
00074254003
00074379701
00074379902
00074379903
00074379906
00074379971
00074433901
00074433902
00074433906
00074433907
00074433971
00074433973
00074433974
00074634702
00074937402
00074937471
58406042534
58406043504
58406044504
58406045504

Enbrel (etanercept)
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Healthcare Common
Procedure Coding
System (HCPCS)
J0135

J1438
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